SCHEMBL4301946

SCHEMBL4301946

CN1CCN(c2cccc(C(=O)N3CCCC(c4ccccc4F)C3)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 3/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B14 Q9BPX1 1/20 0.48
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPK1 P28482 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.42
NAMPT P43490 1/20 0.42
PRKCQ Q04759 1/20 0.41
TP53BP1 Q12888 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4304173 0.93 HSD17B14 (0.47) PROKR1KMT2AHSD17B14MAPTNPSR1
SCHEMBL4301974 0.92 HSD17B14 (0.51) PROKR1KMT2AHSD17B14MAPTRAB9A
SCHEMBL3467150 0.89 HSD17B14 (0.50) KMT2AHSD17B14MAPTRAB9AL3MBTL1
SCHEMBL4301528 0.83 SCD5 (0.53) PROKR1KMT2AHSD17B14RAB9AALDH1A1
SCHEMBL3466779 0.82 HSD17B14 (0.49) KMT2AHSD17B14MAPK1SMN1; SMN2USP2
SCHEMBL3467772 0.81 HSD17B14 (0.48) KMT2AHSD17B14MAPK1SMN1; SMN2USP2
SCHEMBL4300878 0.80 PROKR1 (0.46) PROKR1KMT2AHSD17B14MAPTNPSR1
SCHEMBL3469979 0.80 USP2 (0.52) KMT2AHSD17B14MAPK1SMN1; SMN2USP2
SCHEMBL4294490 0.80 HSD17B14 (0.48) KMT2AHSD17B14MAPK1SMN1; SMN2USP2
SCHEMBL4294496 0.80 HSD17B14 (0.48) KMT2AHSD17B14MAPK1SMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 PROKR1 563/4885KMT2A 1807/4885HSD17B14 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.